Prothrombin time-international normalized ratio is a useful marker for edoxaban efficacy in preventing venous thromboembolism after total knee arthroplasty
- PMID: 28766070
- DOI: 10.1007/s00590-017-2018-5
Prothrombin time-international normalized ratio is a useful marker for edoxaban efficacy in preventing venous thromboembolism after total knee arthroplasty
Abstract
Background: Deep vein thrombosis (DVT) is one of the main complications following total knee arthroplasty (TKA). In this study, oral administration of 15 mg edoxaban (a factor Xa inhibitor) once daily for 14 days efficiently prevented the incidence of DVT. Our hypothesis was that prothrombin time-international normalized ratio (PT-INR) on the third postoperative day could predict the incidence of DVT following TKA.
Methods: In this study, 286 subjects were enrolled and divided into two groups according to the presence or absence of DVT. Several variables [age, body mass index, postoperative D-dimer level, PT-INR, and functional recovery findings (standing)] were analysed to determine the predictors of DVT, and for DVT diagnosis, ultrasonography was performed for seven days after surgery.
Results: The PT-INR levels were significantly higher in the group that did not develop DVT (p = 0.01). Further analysis with logistic regression analysis and receiver operating characteristic curve was performed. The PT-INR on the third postoperative day was an independent factor of the incidence of DVT (odds ratio 0.210; p = 0.035). The cut-off PT-INR was calculated to be 1.425.
Conclusion: PT-INR level is a useful marker in determining whether 15 mg edoxaban administration can prevent DVT after TKA. It is suggested that increment of edoxaban to control PT-INR over the cut-off point might prevent the incidence of DVT.
Keywords: Deep vein thrombosis (DVT); Edoxaban; Functional recovery; Prothrombin time-international normalized ratio (PT-INR); Total knee arthroplasty.
Similar articles
-
Clinical Assessment of Postoperative Anemia Associated with Edoxaban in Patients Undergoing Total Knee Arthroplasty Compared to Fondaparinux.Biol Pharm Bull. 2016;39(4):516-23. doi: 10.1248/bpb.b15-00713. Biol Pharm Bull. 2016. PMID: 27040624
-
A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty.J Orthop Sci. 2018 Nov;23(6):1005-1010. doi: 10.1016/j.jos.2018.06.004. Epub 2018 Jul 4. J Orthop Sci. 2018. PMID: 30431004 Clinical Trial.
-
Edoxaban is effective in reducing the incidence of asymptomatic phlebographic events following closed-wedge high tibial osteotomy.Orthop Traumatol Surg Res. 2017 Dec;103(8):1193-1196. doi: 10.1016/j.otsr.2017.07.016. Epub 2017 Sep 18. Orthop Traumatol Surg Res. 2017. PMID: 28928048 Clinical Trial.
-
Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining.Ann Pharmacother. 2012 Jan;46(1):79-88. doi: 10.1345/aph.1P626. Epub 2011 Dec 27. Ann Pharmacother. 2012. PMID: 22202495 Review.
-
Influence of diabetes on the risk of deep vein thrombosis of patients after total knee arthroplasty: a meta-analysis.J Orthop Surg Res. 2024 Mar 4;19(1):164. doi: 10.1186/s13018-024-04624-z. J Orthop Surg Res. 2024. PMID: 38439085 Free PMC article.
Cited by
-
International Normalized Ratio Predicts Recurrence and Bleeding in Patients With Acute Venous Thromboembolism Who Undergo Direct Oral Anticoagulants.Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241246004. doi: 10.1177/10760296241246004. Clin Appl Thromb Hemost. 2024. PMID: 38566600 Free PMC article.
-
Assisting significance of lncRNA ASB16-AS1 in the early detection and prognosis prediction of patients with deep venous thrombosis.BMC Cardiovasc Disord. 2025 Feb 8;25(1):89. doi: 10.1186/s12872-025-04487-0. BMC Cardiovasc Disord. 2025. PMID: 39923021 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical